Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola Virus Immuno-assay Requires Fewer Study Participants to Power a Study Than the Alpha Diagnostic International Assay

Overview

Journal J Virol Methods

Specialty Microbiology

Date 2018 Feb 27

PMID 29481881

Citations 20

Authors

James Logue

Kaylie Tuznik

Dean Follmann

Greg Grandits

Jonathan Marchand

Cavan Reilly

Yeya Dit Sadio Sarro

James Pettitt

Eric J Stavale

Mosoka Fallah

Gene G Olinger

Fatorma K Bolay

Lisa E Hensley

Affiliations

Soon will be listed here.

Abstract

As part of the scientific community's development of medical countermeasures against Ebola virus disease, optimization of standardized assays for product evaluation is paramount. The recent outbreak heightened awareness to the scarcity of available assays and limited information on performance and reproducibility. To evaluate the immunogenicity of vaccines entering Phase I-III trials and to identify survivors, two enzyme-linked immunosorbent assays, the Filovirus Animal Non-Clinical Group assay and the Alpha Diagnostics International assay, were evaluated for detection of immunoglobulin G against Ebola virus glycoprotein. We found that the Filovirus Animal Nonclinical Group assay produced a wider range of relative antibody concentrations, higher assay precision, larger relative accuracy range, and lower regional background. Additionally, to sufficiently power a vaccine trial, use of the Filovirus Animal Nonclinical Group assay would require one third the number of participants than the Alpha Diagnostics International assay. This reduction in needed study participants will require less money, fewer man hours, and much less time to evaluate vaccine immunogenicity.

Citing Articles

Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial.

Davey Jr R, Collins G, Rouphael N, Poliquin G, McConnell R, Grubbs G Lancet Microbe. 2024; 5(11):100923.

PMID: 39374605 PMC: 11560587. DOI: 10.1016/S2666-5247(24)00163-0.

Ebola Virus-Specific Neutralizing Antibody Persists at High Levels in Survivors 2 Years After Resolution of Disease in a Sierra Leonean Cohort.

Bond N, Shore K, Engel E, Coonan E, Al-Hasan F, Gbakie M J Infect Dis. 2024; 230(4):e929-e937.

PMID: 38801652 PMC: 11481455. DOI: 10.1093/infdis/jiae155.

Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.

Ake J, Paolino K, Hutter J, Cicatelli S, Eller L, Eller M Vaccines (Basel). 2024; 12(5).

PMID: 38793748 PMC: 11125575. DOI: 10.3390/vaccines12050497.

Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.

Lariviere Y, Garcia-Fogeda I, Zola Matuvanga T, Isekah Osangir B, Milolo S, Meta R J Infect Dis. 2023; 229(4):1068-1076.

PMID: 37673423 PMC: 11011182. DOI: 10.1093/infdis/jiad350.

Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo.

Zola Matuvanga T, Marien J, Lariviere Y, Isekah Osangir B, Milolo S, Meta R PLoS One. 2023; 18(9):e0286479.

PMID: 37656725 PMC: 10473486. DOI: 10.1371/journal.pone.0286479.

References

Arias A, Watson S, Asogun D, Tobin E, Lu J, Phan M . Rapid outbreak sequencing of Ebola virus in Sierra Leone identifies transmission chains linked to sporadic cases. Virus Evol. 2017; 2(1):vew016. PMC: 5499387. DOI: 10.1093/ve/vew016. View

Pushko P, Bray M, Ludwig G, Parker M, Schmaljohn A, Sanchez A . Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine. 2000; 19(1):142-53. DOI: 10.1016/s0264-410x(00)00113-4. View

Fischer R, Judson S, Miazgowicz K, Bushmaker T, Munster V . Ebola Virus Persistence in Semen Ex Vivo. Emerg Infect Dis. 2016; 22(2):289-91. PMC: 4734518. DOI: 10.3201/eid2202.151278. View

Uyeki T, Erickson B, Brown S, McElroy A, Cannon D, Gibbons A . Ebola Virus Persistence in Semen of Male Survivors. Clin Infect Dis. 2016; 62(12):1552-1555. DOI: 10.1093/cid/ciw202. View

Blackley D, Wiley M, Ladner J, Fallah M, Lo T, Gilbert M . Reduced evolutionary rate in reemerged Ebola virus transmission chains. Sci Adv. 2016; 2(4):e1600378. PMC: 4928956. DOI: 10.1126/sciadv.1600378. View

Yang W, Zhang W, Kargbo D, Yang R, Chen Y, Chen Z . Transmission network of the 2014-2015 Ebola epidemic in Sierra Leone. J R Soc Interface. 2015; 12(112). PMC: 4685836. DOI: 10.1098/rsif.2015.0536. View

Fischer 2nd W, Wohl D . Confronting Ebola as a Sexually Transmitted Infection. Clin Infect Dis. 2016; 62(10):1272-6. PMC: 4845792. DOI: 10.1093/cid/ciw123. View

Mate S, Kugelman J, Nyenswah T, Ladner J, Wiley M, Cordier-Lassalle T . Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med. 2015; 373(25):2448-54. PMC: 4711355. DOI: 10.1056/NEJMoa1509773. View

Crozier I . Ebola Virus RNA in the Semen of Male Survivors of Ebola Virus Disease: The Uncertain Gravitas of a Privileged Persistence. J Infect Dis. 2016; 214(10):1467-1469. DOI: 10.1093/infdis/jiw079. View

10.

Findlay J, Dillard R . Appropriate calibration curve fitting in ligand binding assays. AAPS J. 2007; 9(2):E260-7. PMC: 2751416. DOI: 10.1208/aapsj0902029. View

11.

MacDermott N, Bausch D . Virus persistence and recrudescence after Ebola virus disease: what are the risks to healthcare workers?. J Hosp Infect. 2016; 94(2):113-5. DOI: 10.1016/j.jhin.2016.07.004. View

12.

Sow M, Etard J, Baize S, Magassouba N, Faye O, Msellati P . New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors. J Infect Dis. 2016; 214(10):1475-1476. DOI: 10.1093/infdis/jiw078. View

13.

Kennedy S, Bolay F, Kieh M, Grandits G, Badio M, Ballou R . Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N Engl J Med. 2017; 377(15):1438-1447. PMC: 5705229. DOI: 10.1056/NEJMoa1614067. View

14.

Wilson J, HART M . Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol. 2001; 75(6):2660-4. PMC: 115890. DOI: 10.1128/JVI.75.6.2660-2664.2001. View

15.

Wong G, Richardson J, Pillet S, Patel A, Qiu X, Alimonti J . Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med. 2012; 4(158):158ra146. PMC: 3789651. DOI: 10.1126/scitranslmed.3004582. View

16.

Deen G, Broutet N, Xu W, Knust B, Sesay F, McDonald S . Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Final Report. N Engl J Med. 2015; 377(15):1428-1437. PMC: 5798881. DOI: 10.1056/NEJMoa1511410. View

17.

Kennedy S, Neaton J, Lane H, Kieh M, Massaquoi M, Touchette N . Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. Clin Trials. 2016; 13(1):49-56. DOI: 10.1177/1740774515621037. View

18.

Xu L, Sanchez A, Yang Z, Zaki S, Nabel E, Nichol S . Immunization for Ebola virus infection. Nat Med. 1998; 4(1):37-42. DOI: 10.1038/nm0198-037. View